menu
    • menu

    Company profile for Ratio Therapeutics

    NEW Drugs in Dev: 3
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    Arlanda is your partner for the Brazil market.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer ta...
    A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics".

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ratio TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    77 Sleeper St, Boston, MA 02210
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ratiotx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ratio-therapeutics/about/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    PBP World Meeting

    Not Confirmed

    envelop Contact Supplier

    PBP World Meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ratio Therapeutics Names Colin Hayward Chief Medical Officer
    Ratio Therapeutics Names Colin Hayward Chief Medical Officer

    12 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ratio-therapeutics-appoints-global-medical-leader-colin-hayward-as-chief-medical-officer-302711578.html

    PR NEWSWIRE
    12 Mar 2026
    Share Share
    PharmaLogic Delivers First Doses for Ratio Therapeutics' FAP
    PharmaLogic Delivers First Doses for Ratio Therapeutics' FAP

    16 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pharmalogic-announces-successful-supply-of-first-cohort-dosing-for-ratio-therapeutics-phase-12-study-of-a-novel-fap-targeted-radiopharmaceutical-in-late-stage-aggressive-sarcomas-302643412.html

    PR NEWSWIRE
    16 Dec 2025
    Share Share
    Ratio Therapeutics Doses Cohort in Phase 1/2 FAP Trial
    Ratio Therapeutics Doses Cohort in Phase 1/2 FAP Trial

    16 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ratio-therapeutics-has-successfully-dosed-the-first-cohort-in-its-phase-12-study-evaluating-a-novel-fap-targeted-radiopharmaceutical-in-patients-with-late-stage-aggressive-sarcomas-302642494.html

    PR NEWSWIRE
    16 Dec 2025
    Share Share
    Ratio Therapeutics Names Marcel Reichen Chief Strategy Officer
    Ratio Therapeutics Names Marcel Reichen Chief Strategy Officer

    04 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ratio-therapeutics-announces-the-appointment-of-marcel-reichen-as-chief-strategy-officer-302603416.html

    PR NEWSWIRE
    04 Nov 2025
    Share Share
    Ratio & TerraPower Sign Actinium-225 Supply Agreement
    Ratio & TerraPower Sign Actinium-225 Supply Agreement

    20 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ratio-therapeutics-and-terrapower-isotopes-sign-supply-agreement-for-actinium-225-for-targeted-radiotherapeutics-302486450.html

    PR NEWSWIRE
    20 Jun 2025
    Share Share
    Ratio, Nusano Ink Multi-Isotope Pact For Cancer Drugs
    Ratio, Nusano Ink Multi-Isotope Pact For Cancer Drugs

    17 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ratio-therapeutics-and-nusano-enter-long-term-multi-isotope-supply-agreement-to-boost-production-of-cancer-radiopharmaceuticals-302482654.html

    PR NEWSWIRE
    17 Jun 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search